CHPA Response to Study Examining Prescription Acid Reflux Drugs

Share page:

“This study only evaluated the prescription use of proton pump inhibitors (PPIs), H2 receptor antagonists (H2RAs), or other antacids, and did not assess over-the-counter (OTC) use of these medicines. This is a critical distinction, as prescription heartburn medicines are typically used at higher doses, for longer durations, and for more severe conditions than OTC heartburn medicines. Additionally, the American Academy of Neurology (AAN) notes that this study does not prove that acid-reducing drugs cause migraines and that more research is needed. 

“OTC heartburn medicines are only indicated for use for occasional or frequent heartburn, not for chronic heartburn or reflux disease (GERD) and are labeled only for short-term use. OTC medicines are regulated by the U.S. Food and Drug Administration (FDA), and each OTC medicine has a clear Drug Facts label to help consumers understand what the medicine is used for, proper dosing and duration of use, and any drug interactions. 

“OTC medicines provide a tremendous benefit to consumers and the U.S. healthcare system overall. Previous research from CHPA and the Nielsen Company indicates 94% patient satisfaction with OTC heartburn medications and estimates that OTC therapy saves patients an average total of $174 each in office visits and medication costs annually. CHPA is supportive of continued research and consumer education to help ensure safe use of OTC medicines.”

The Consumer Healthcare Products Association (CHPA) Educational Foundation is a 501 (c)(3) nonprofit organization that empowers consumers to make smart self-care decisions by providing information and guidance on how to safely use, store, and dispose of OTC medicines and dietary supplements. Its mission is to serve as the trusted source of information on the responsible use of consumer healthcare products. Visit or for more information.